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Abstract
Background: Nosocomial infections are the most common complication during inpatient hospital care. An
increasing proportion of these infections are caused by multidrug-resistant organisms (MDROs). This report
describes an intervention study which was designed to address the practical problems encountered in trying
to avoid and treat infections caused by MDROs. The aim of the HARMONIC (Harmonized Approach to avert
Multidrug-resistant Organisms and Nosocomial Infections) study is to provide comprehensive support to hospitals in a
defined study area in north-east Germany, to meet statutory requirements. To this end, a multimodal system
of hygiene management was implemented in the participating hospitals.
Methods/design: HARMONIC is a controlled intervention study conducted in eight acute care hospitals in the ‘Health
Region Baltic Sea Coast’ in Germany. The intervention measures include the provision of written recommendations on
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE) and multi-resistant
Gram-negative bacteria (MRGN), supplemented by regional recommendations for antibiotic prescriptions. In
addition, there is theoretical and practical training of health care workers (HCWs) in the prevention and handling of
MDROs, as well as targeted and critically gauged applications of antibiotics.
The main outcomes of the implementation and analysis of the HARMONIC study are: (i) screening rates for MRSA,
VRE and MRGN in high-risk patients, (ii) the frequency of MRSA decolonization, (iii) the level of knowledge of
HCWs concerning MDROs, and (iv) specific types and amounts of antibiotics used.
The data are predominantly obtained by paper-based questionnaires and documentation sheets. A computer-assisted
workflow-based documentation system was developed in order to provide support to the participating facilities. The
investigation includes three nested studies on risk profiles of MDROs, health-related quality of life, and cost analysis. A
six-month follow-up study investigates the quality of life after discharge, the long-term costs of the treatment
of infections caused by MDROs, and the sustainability of MRSA eradication.
(Continued on next page)
* Correspondence: miriam.gerlich@bzga.de
1Institut für Community Medicine, Ernst-Moritz-Arndt-Universität,
Ellernholzstraße 1-2, 17487 Greifswald, Germany
Full list of author information is available at the end of the article
© 2015 Gerlich et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gerlich et al. BMC Infectious Diseases  (2015) 15:441 
DOI 10.1186/s12879-015-1184-5
(Continued from previous page)
Discussion: The aim of this study is to implement and evaluate an area-wide harmonized hygiene program to control
the nosocomial spreading of MDROs. Comparability between the intervention and control group is ensured by
matching the hospitals according to size (number of discharges per year / number of beds) and level of care
(standard or maximum). The results of the study may provide important indications for the implementation of
regional MDRO management programs.
Keywords: Nosocomial infections, Multidrug-resistant organisms, MRSA, VRE, MRGN, Antibiotic use, Hospital
hygiene, Costs, Health-related quality of life
Background
Nosocomial infections are the most common complica-
tion that can occur during inpatient hospital care [1],
and antimicrobial resistance is a serious threat to public
health [2]. The Second European Point Prevalence Sur-
vey 2011–2012, involving 30 countries, showed that
6.0 % of the 231,459 surveyed patients had a healthcare-
associated infection. The prevalence varied widely de-
pending on country and type of ward, however [3]. In a
sample of 9,626 patients from 46 hospitals in Germany,
5.1 % suffered from a nosocomial infection. 66 % of
those infections (3.4 % of the whole sample) had arisen
during the current hospital stay [4]. A significant pro-
portion of these infections are caused by multidrug-
resistant organisms (MDROs), with methicillin-resistant
Staphylococcus aureus (MRSA) as the main cause [5, 6].
In Germany, the prevalence of MRSA has been nearly
stable in recent years, with an 18 to 20 % resistance rate
in clinical Staphylococcus aureus isolates [7]. It has, on
the other hand, slightly decreased in high risk settings
such as intensive care and surgical wards, where the pro-
portion of MRSA among nosocomial Staphylococcus
aureus infections decreased from 33 % to 27 % in the
period from 2007 to 2012 [8]. In contrast, there has been
a rise in the number of multiresistant Gram-negative
bacteria (MRGN), such as third-generation cephalosporin
(3GC)-resistant Escherichia coli and 3GC-resistant
Klebsiella pneumoniae [9–12]. The prevalence of vanco-
mycin resistance is also increasing in Germany, but this is
mainly restricted to strains of E. faecium. The rate of
vancomycin resistance in clinical E. faecium isolates varies
between 8 and 15 %, with local and regional variability
ranging from 0 % to over 30 % [13].
International studies have shown that between 10 and
70 % of nosocomial infections could have been pre-
vented. Important factors involved in this variation were
setting, study design, baseline infection rates and type of
infection [14].
When planning infection control measures, it has to
be taken into consideration that patients move freely be-
tween acute care and rehabilitation facilities, as well as
within the ambulant sector [15]. Therefore, hospitals
should not be viewed as isolated units, but rather as
connected elements of a larger modular network, requir-
ing a regional approach [16]. In the Baltic Sea Coast re-
gion, the joint research project HICARE (Health,
Innovative Care And Regional Economy) was initiated in
2011 to improve control of MDROs in north-east
Germany. HICARE is supported by public funds and sup-
plemented by industrial contributions. A basic element of
the HICARE project is the implementation of a multi-
modal hygiene program in the acute care hospitals of
the region, which was developed within the frame-
work of the HICARE project and included all German
statutory specifications for infection protection. The
governmental recommendations for the prevention
and control of multiresistant organisms are mandatory
for medical facilities, as specified by the July 2011 re-
vision of the German Infection Protection Act (Infek-
tionsschutzgesetz) [17]. To date, nationwide mandatory
recommendations have been issued for MRSA [18–20]
and, more recently, for MRGN [9, 21]. In addition to these
two groups of causative organisms, the HICARE program
includes recommendations for dealing with VRE.
To include the patient’s point of view and experi-
ence, the current study contains a patient evaluation
sheet on hospital hygiene practice, and examines as
well the health-related quality of life of patients with
MDROs. Only few studies have been published on
these aspects. Analyses of the costs and benefits of
measures to reduce multidrug-resistant organisms are
also scarce in Germany [22, 23].
One problem that arises with pre- and post-studies to
determine the effects of intervention measures is the fact
that changes in statutory requirements over time often
affect the results. Therefore, the present study is de-
signed as a prospective, controlled intervention study.
Since the goal is to implement the HICARE hygiene pro-
gram in all participating hospitals, those in the control
group will obtain the intervention measures immediately
after completion of the study phase I (delayed-interven-
tion group; see also Fig. 2).
The primary objectives of the intervention are:
 Early detection of MDRO carriers to prevent
complications and transmissions to other patients
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and hospital personnel through consistent hygiene
measures
 Improvement in decolonization of MRSA patients
 Improvement in regional resistance profiles by a
targeted and critically assessed use of antibiotics
As this study focuses on the area-wide implementa-
tion of statutory regulations, it is strictly speaking not
a clinical study, and it was therefore not registered as a
clinical trial. The Ethics Committee approval numbers are:
BB 64/12 (Medical Committee of the University Medicine
Greifswald) and A 2013–0037 (Medical Ethics Committee
of the University Medicine Rostock).
Methods and design
Design overview and setting
A total of 12 hospitals providing acute care participate in
the HICARE project. Due to lack of personnel and time
resources, four of these hospitals could not participate in
the HARMONIC study. Therefore, the study was con-
ducted in eight hospitals in the Health Region Baltic Sea
Coast in Germany (Fig. 1). The study was designed as an
18-month prospective intervention study, which aims at
implementing a multimodal hygiene management pro-
gram. The recruitment of study hospitals started right
after ethics approval (29th of May 2012). Hospitals were
randomized concerning the immediate implementation of
the intervention program versus the campaign starting
with a six-month delay, in four strata of two hospitals
each. The strata were defined by level of care (maximum
care versus standard care) and hospital size (>25,000;
10,000 to 25,000; 5,000 to 10,000; and < 5,000 annual dis-
charges). Table 1 shows the characteristics used to match
the participating hospitals in according pairs. The hospi-
tals in the delayed-intervention group received the inter-
vention measures after completion of the first phase of the
study (Fig. 2). Data collection started in February 2013
and was finished for the main study in November 2014.
Analysis will be finished in June 2015 and December 2015
for two of the nested studies.
Data were collected at the beginning and the end of
each study phase. These data include structural data and
the level of knowledge of hospital personnel with regard
to MDROs. Furthermore, patients in selected wards
were monitored for a period of six months in each study
phase (see also Fig. 2). To maximize comparability of the
participating hospitals, data were obtained for compar-
able subsets of three wards, each including a conserva-
tive intensive care ward, an internal medicine ward and
a surgical ward. According to the specific structure and
procedures of the hospital, an emergency ward was also
included where applicable.
Various groups of MDROs were investigated in this study:
MRSA, VRE and MRGN. Multiresistant Gram-negative
organisms were defined according to the guidelines of
KRINKO (German commission for hospital hygiene
and infection protection) for MRGN [21]. This classi-
fies MRGN into three groups, based on the susceptibil-
ity to four of the most clinically important groups of
antibiotics (acylureidopenicillins, quinolones, 3rd gen.
cephalosporines, carbapenems): 3MRGN is resistant to
three of the four groups, 4MRGN is resistant to four of the
four groups, and strains resistant to less than three groups
are classified as non-multiresistant. The underlying mecha-
nisms (e.g. ESBL, CPE) are not considered in this classifica-
tion. Since the ability to accumulate extended-spectrum
beta-lactamase (ESBL) is still partly used to categorize or-
ganisms, this was also included in the data collection.
The facilities participating in this study are acute care
hospitals in the Health Region Baltic Sea Coast and ad-
jacent hospitals, including two hospitals with maximum
care status (tertiary care; major hospitals with specific
sub-specialty care), and six public and private acute
care hospitals with basic and standard care (secondary
care; the range of services is restricted to prevalent con-
ditions and a typical range of risks).
Recruitment of patients and informed consent
Written informed consent was obtained for participation
in this study. The patients could accept or refuse certain
aspects of participating in the study: the forwarding of
personal data to an independent trust agent, the pseudo-
nymized storage of treatment data in a research data-
base, the possibility of being recontacted at a later date
for follow-up purposes, and the authorization to contact
health care-related people or institutions, such as their
family doctors or health insurance. Basic, anonymous in-
formation on refusal was tracked (gender and age) and
considered in the analysis.
Hypotheses
The intervention is expected to lead to:
 An increased screening rate of persons at risk for
MDROs
 An increase in MRSA decolonization where
indicated
 An increase in knowledge of the healthcare
personnel about the prevention and handling of
MDROs, e.g. treatment of infections
 A lower rate of antibiotic prescriptions
 A higher use of hand and surface disinfectants
Intervention / hygiene measures
The HICARE intervention is based on (A) system change
(hygiene regime) and (B) behavior change methods:
(A) Existing hygiene regimes of the participating hos-
pitals were adapted to the HICARE hygiene program by
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a joint coordination process (harmonized approach). A
goal plan was set up to support necessary improvements,
based on a comparison of the status quo and the targets
of the intervention, documented via a standardized table
sheet. While planning the implementation of the interven-
tion, findings to change management in the field of hy-
giene measures were considered [24]. For example, it was
important to continuously interact with the responsible
hygiene specialists at each study site (doctors and
nursing staff ). These persons also acted as coordina-
tors on site.
(B) To accomplish behavioral change, behavior-
centered theoretical frameworks were taken into consid-
eration [25–27]. Key aspects from multiple domains
were addressed during conception of the intervention,
such as: knowledge, skills, self-efficacy, beliefs about
consequences, motivation and goals, memory, attention
and decision processes, and the environmental context
and resources (e.g. physical resources, management as-
pects). Several behavior change methods were taken
into account [26, 28] and applied to the different mod-
ules of the intervention.
Evidence-based, pathogen-specific recommendations for
the prevention and handling of MRSA, VRE and MRGN
were drafted within the framework of the HICARE
program, including governmental recommendations. The
HICARE recommendations, which also include regional
recommendations for the initial prescription of antibiotics
for adults, represent the basis for the intervention.
The constituent parts of the intervention and the mea-
sures to promote the implementation are described in
Table 2.
Fig. 1 Health Region Baltic Sea Coast — hospitals participating in the study
Table 1 Characteristics used to match the study hospitals
Number of discharges/yeara Number of bedsa Level of careb Matching pair
(Precision: 103) (Precision: 102)
Hospital 1 40,000 1,000 maximum A
Hospital 2 35,000 900 maximum A
Hospital 3 23,000 500 standard B
Hospital 4 10,000 200 standard B
Hospital 5 7,000 200 standard C
Hospital 6 7,000 100 standard C
Hospital 7 4,000 100 standard D
Hospital 8 4,000 100 standard D
aData refer to the year 2010
bLevels of care (maximum care or standard care)
-maximum care hospitals: tertiary care; major hospitals with specific sub-specialty care
-standard care hospitals: secondary care; the range of services is restricted to prevalent conditions and a typical range of risks
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Screening and diagnostic procedure
The following sites were screened for MRSA, according
to the HARMONIC intervention: pooled nasal swab
(both nostrils), throat and wounds or catheter positions
if infected by bacterial culture. The laboratory diagnosis
of MRSA differs in the participating hospitals, depending
on availability of methods:
 PCR, if PCR is positive: confirmation by culture,
 only by culture or
 mainly by culture, unless a fast result by PCR is
necessary.
Sites of screening for VRE include stool samples, and
in exceptional cases rectal swabs. Detection of VRE is
done by culture.
Sites of screening for MRGN are:
 Enterobacteria: stool sample and rectal swab;
anatomic sites with former positive MRGN results;
materials from potentially infected body fluids such
as urine, wound secretions, tracheal secrete, blood
culture and further stool samples or rectal swabs,
 Multiresistant non-fermenting organisms: throat
swab, large-scale skin swab (A. baumannii).
Diagnostic results are obtained by culture.
Collaboration with industry
The research institutions that organized this joint project
cooperate with the healthcare management companies
that take part in the HICARE project, as requested by the
federal funding organization. The following materials used
during the intervention phase were provided by the com-
panies: automatic hand disinfectant dispensers, sterile
water filters for intensive care wards, confectioned MRSA
treatment kits for standardized decolonization, and care




 Screening rates for MRSA, VRE and MRGN in risk
patients
Secondary outcomes:
 Frequency of MRSA decolonization upon indication
 Level of knowledge about MDROs by the nursing
staff and physicians
 Types and amounts of antibiotics use
 Use of hand and surface disinfectants
Nested studies
Analysis of risk profiles for multidrug-resistant organisms in
patients screened for MDROs
The risk profiles of patients who tested positive for
MDROs at admission was compared to patients who
tested negative. Analyses will be performed for MDROs
in general, as well as for individual groups of pathogens,
as examined in the HARMONIC study.
Fig. 2 Cluster-specific study phases
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Table 2 Constituent parts of the intervention and measures to promote the implementation
Constituent parts of the intervention Measures to promote the implementation
1. Theoretical and practical training courses for HCWs by the study team in:
risk-based MDRO screening, isolation in suspected and confirmed cases
of MDRO, treatment of MDRO cases including evidence-based
decolonization protocol for MRSA, general measures to prevent MDROs
(standard hygienic measures such as disinfection of hands and bed site
surfaces, protective clothing)
For each hospital, together with the coordinator on-site, several alternative appointments
were set up for each training course. Thus, it was possible that nearly all HCWs of the
participating wards could join the courses.
The courses were registered by the medical associations as advanced training, which
adds to the attractiveness of the course.
2. Instructions on treatment of MDRO including an evidence-based
decolonization protocol for MRSA ( The first line therapy for MRSA
decolonization in the HARMONIC intervention was Mupirocin nasal
ointment. In case of Mupirocin-resistance, polihexanide nasal
ointment was used. For antisepsis of buccal cavity octenidine is used,
alternatively polihexanide.)
The computer-assisted system ensures the implementation of the intervention by a
step by step guidance.
Pocket cards for the decolonization protocol for
MRSA were provided.
3. Instruction courses by the study team for physicians on the
recommendations for use of antibiotics
Several alternative appointments were offered to achieve a high participation rate. The
courses were registered by the medical associations as advanced training, which adds
to the attractiveness of the course.
4. Provision of detailed information material on the intervention A folder with the course material was available on each ward. Information was
additionally provided via a study website (separate log in for intervention hospitals).
5. Posters to intervention measures and application of study instruments They function as a reminder.
6. Pocket cards for screening regime and decolonization protocol,
see also point 2.
They function as a reminder.
7. Periodic on-site visits by the study team to provide advisory support
on the implementation of the intervention measures and documentation
of the improvement
The documentation was done via table structure and text fields. Feedback on performance was given
(sources: on-site visits and monitoring process)
8. Provision of a “hotline” for questions to the intervention measures,
manned by experts in hospital hygiene, who belonged to the study team
Requests of HCWs of the participating wards to single intervention measures could be
answered timely.
Furthermore, questions were documented anonymously and are used in the evaluation
process of the study.














Analysis of health-related quality of life of MDRO carriers
To define the impact of MDRO infection or carrier-
ship on quality of life, a matched analysis was per-
formed (ratio 1:1). The health-related quality of life
for patients who tested positive for MDROs will be
compared to patients who tested negative and who
were admitted in the participating wards of the same hos-
pital. Matching criteria will include sex, age (+/− 5 years)
and severity of illness. The patient-reported SF-36 Health
Survey as modified for use in a hospital setting [29]
is to be filled out shortly before discharge from the
participating ward.
Analysis of MDRO-related hospital costs
A further study will assess the costs of MDRO man-
agement in hospitalized patients. The analysis is based
on the data from the documentation sheet on the
progression of MDRO status, and from the documen-
tation sheet for nursing efforts. Additionally, lengths
of hospital stay and other parameters relating to the
German Diagnosis Related Group payment system
will be evaluated with a focus on remuneration ef-
fects. MDRO-positive patients will be compared with
MDRO-negative patients (separately for each patho-
gen) via matching analysis (ratio 1:3). Matching vari-
ables are the main discharge diagnosis (ICD-10) and
the type of discharging ward.
Follow-up examinations
A six-month follow-up program is planned for patients
taking part in the study and who have been screened for
MDRO during their hospital stay. This program is di-
vided into three parts:
1. Health-related quality of life: quality of life survey six
months after discharge from hospital, in comparison
to patients who were tested negative for MDRO
during their time as in-patient (control group). To
this end, the modified SF-36 form will be sent by
mail to the home addresses by the independent trust
agency including a return mail envelope addressed
to the trust agency.
2. Sustainability of MRSA decolonization: MRSA
status will be determined by culture diagnosis six
months after discharge from hospital. For this
test, a trained nurse will visit the patient at home
and take a nasal and, if requested, throat and/or
wound swab. The sample will be sent to a central
laboratory.
3. Health care utilization over a period of six months
after discharge for patients who were screened for
MDRO during their hospital stay. The data for
positive patients are compared to those with
negative results. For this reason, a patient-reported
questionnaire including a reply-paid envelope will
be sent to the home address by the independent
trust agency. Secondary data of health insurance
companies will be analyzed as well.
In each case, the accompanying informed consent
policies have to be agreed by the patient.
Methods of data collection and variables
1. Baseline data collection conducted with participating
hospitals included a questionnaire to assess
structural parameters (e.g. number of beds/cases/
single rooms, staffing ratio, staff level of
qualification, prevalence of advanced training in
hygiene), and process parameters (procedures of
registering, documentation and reporting of
MDROs). At the end of each study phase (Fig. 2),
potential changes in structural or process
parameters were documented, together with use of
antibiotics and disinfectants for the given period.
2. Data on the use of antibiotics and disinfectants over
the three years prior to this study, as well as test
utilization and resulting positive MDRO rates, were
documented by the study team.
3. The level of knowledge of the nursing staff and
physicians on MDROs was assessed by a multiple
choice test at the beginning of the instructional
courses.
4. Structured questionnaires and documentation forms
were used during the intervention period, and, for
the delayed-intervention group only, during the
observation period, identical for all hospitals (Table 3).
The usage of the questionnaires for the collection of
patient data is shown in the flow chart in Fig. 3. Partici-
pation was only requested if the patient was expected to
remain in the ward for at least 48 hours. The patient ad-
mission sheet and both MDRO documentation sheets
were designed to replace the previous documentation
used by the hospitals. This measure also avoids time and
effort of double documentation. The treatment sheets
are designed such that the original has space for a label
with the patient’s identification and is included in the
patient’s file as treatment documentation after the pa-
tient is discharged. For the sake of data privacy protec-
tion, the carbon copy that is used for our concomitant
research will not have a label with patient identifying
data. Both the original and the carbon copy are provided
with a document barcode, allowing a mapping of mul-
tiple documents to a single pseudonym and preserving
anonymity for non-consenters.
A workflow-oriented documentation system was de-
veloped that is made available to the participating wards
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on a tablet PC, a Medical Clinical Assistant (MCA) with
an integrated barcode scanner and a touch screen that
can be disinfected. This system serves two purposes:
i. Support during the study
Upon admission of a patient who is expected to
spend at least 48 hours on the ward, the basic data
(given name, surname, and date of birth) are entered
into the system. The system then guides the staff
through the sequence required by the study
according to the individual patient, indicating which
forms are to be filled out at which time. After
completion, the forms respectively their copies are
dropped into a special mailbox and are subsequently
transferred to a central data management. Patient
permissions are collected in a separate container and
are transferred to the independent trust agent. Staff
members from the participating wards are trained in
how to use the documentation system by HARMONIC
study personnel.
ii. Data privacy protection
Patient data entered into the workflow-oriented
documentation system are encrypted by hospital-
specific private keys and only visible to the
responsible HCWs. To allow the individual forms
and copies to be correlated to a specific person,
each sheet of the form contains an ID that can
be read out by the barcode scanner integrated in
the MCA. This system provides the relational
mapping of the individual sheet IDs to the
participant ID, while assuring the data privacy
protection.
Data management and protection procedures
Monitoring procedures
The workflow-oriented documentation system was de-
veloped as a web-based solution. This allows real-time
monitoring of the individual paper forms, so that any
problem arising with the use of the forms can be quickly
detected and solved. The monitoring dashboard contains
aggregated data on the usage of the forms, but does not
show any data about individuals.
Data protection procedures
A data protection plan was developed for the HARMONIC
study in conjunction with the State Commissioner for Data
Protection and Freedom of Information. If a patient gives
permission to store his or her treatment data under a
pseudonym, the personal identifying data (name, address)
is collected on the informed consent document. Manage-
ment of the consent documents is performed by an inde-
pendent trust agent. Pseudonymized medical data are
stored in a research database separated from the identify-
ing data in an approach (Fig. 4) that follows the recom-
mendations of the “Generic solutions for data protection in
medical research networks – model B”, developed by the
umbrella organization for networked medical research in
Germany (TMF) [30, 31]. These recommendations were
accepted by the German conference of federal and state
data protection commissioners.
The study data originate from primary and secondary
data sources and are registered using document IDs, serv-
ing as study pseudonyms. Identifying data and medical
data are processed as shown in Fig. 4. In the research
database, only double pseudonymized data are stored,
Table 3 Documents used for data acquisition during the intervention and observation phase
Documents used in the intervention
and observation phase
Description of data collected Document to be filled out by
Patient admission sheet Risk factors for MDRO colonization or infection Health care workers during
anamnesis, or, alternatively,
by the patient (with help of staff)
Documentation sheet on the progression
of MDRO status including transition sectiona
for the physician responsible for subsequent
treatment
Admission and discharge data, sample taking
and diagnosis, where applicable isolation
measures, control swab test, time of infection,
information for physician responsible for
subsequent treatment
Health care workers
Documentation sheet for nursing efforts
for MDROb infections/colonizations
Nursing workload in minutes Nursing staff
Patient evaluation sheet Subjective evaluation of hygiene measures
in the hospital
Patient
Quality of life questionnaire (modified version
of the SF-36)
Health-related quality of life in the last
seven days
Patient
aThis form differs slightly for the delayed intervention group and the immediate intervention group. In order to exert as little influence as possible on the
documentation of previous hygiene management programs, the form for the delayed intervention group does not include the transition section for the physician
responsible for subsequent treatment
balso relevant for reimbursement by the statutory health insurance
Note: Documents can be downloaded from: http://www2.medizin.uni-greifswald.de/icm/index.php?id=hicare
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which prevents re-identification of the patient while ana-
lyzing the data. If necessary, further measures will be
taken to impede re-identification, e.g. aggregation or pre-
cision reduction of informative variables such as age.
If no informed consent can be obtained, no identifying




According to German screening recommendations on
MRSA, about 40 % of patients admitted in acute hospi-
tals in Germany have risk factors for MRSA [32]. It has
been shown that screening recommendations are not
followed completely, despite their obligatory character
[33]. Based on information solicited with our institu-
tional questionnaire, not all of the participating hospitals
had fully adapted to the recommendations at baseline.
Thus, as basis for sample size calculations, our interven-
tion was assumed to improve the screening rate in
MRSA risk patients from 60 % (control group) to 90 %
(intervention group). The expected sample of > 1000 pa-
tients in each group results in a very high statistical
power (approaching 1.0) for this study (type-I risk: 0.05).
With an observation period of six months for each
of the 24 participating wards, at least 5,000 patient
admissions with an anticipated stay over 48 hours are
expected. Based on previous examinations [7, 8, 34, 35],
an MRSA prevalence at admission of approximately 1 to
3 % is anticipated. Accordingly, 50 to 150 MRSA positive
patients would be eligible for follow-up examinations.
Data analysis
To evaluate the effect of the outcome measures, a hier-
archical logistic regression model for the log-odds of a
patient’s chance to be screened for either MRSA, VRE,
or MRGN was formulated as follows:
(level 1):
logitðantibiogram ¼ 1Þij ¼ aj þ β1X1ij þ β2X2ij þ⋯þ εij
with
i :¼1 to k patient index
j :¼1 to 8 ID number of hospital
X1 to Xm individual patient chartacteristics;
such as age; sex; surgical treatment etc:
As the intervention program was implemented on the
level of participating hospitals, the following level-2
equation (random intercept model) was a priori specified
for statistical analysis:
aj ¼ γ00 þ γ01ζ1j þ γ02ζ2j þ⋯þ ωj
with γ00 representing the global base rate parameter for
screening tests, and γ0j hospital-specific additions de-
pending on the intervention group (ζ1 = 1 for interven-
tion period, 0 otherwise), hospital capacity (ζ2j measured
on metric scale level) or similar. To test the main hy-
pothesis, the significance of parameter γ01 (deviation
from zero) will be tested. Control for potential center ef-
fects is exerted by introduction of the ωj center-specific
error terms of the intercept parameter.
It will be decided during the model selection process
whether or not other variables on the hospital level are
to be introduced in separate level-2 equations as so-
called random slope-effects (e.g. hospital-specific ten-
dencies towards testing older patients more frequently).
Fig. 3 Patient-specific study workflow — intervention group
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For an assessment of the differences between the
matched groups in the costs of MDRO management and
treatment, as well as in health-related quality of life,
t-tests will be applied. In order to control for the influ-
ence of covariates, likewise multivariate analysis methods
and, in particular, logistic regression analysis will be ap-
plied to address selected issues.
Ethical approval
The study protocol including the nested studies was
endorsed by the Medical Ethics Committee of the
University Medicine Greifswald (BB 64/12) and by the
Medical Ethics Committee of the University Medicine
Rostock (A 2013–0037).
Discussion
The development and implementation of infection
control programs is becoming increasingly important,
since medical care has become more complex and
antimicrobial resistance has increased [15]. Different
management approaches play an important role in
preventing nosocomial infections with MDROs, including
screening of high-risk patients, barrier precautions, com-
pulsory hand hygiene, cleaning and disinfection, and sur-
veillance of infections [15, 22]. Furthermore, there is an
increased interest in MRSA decolonization measures [15,
36]. Study results show that nasal decolonization with
Mupirocin, in combination with other substances, may
lead to a reduction of MRSA infections. However, long-
term effects have so far barely been investigated [22].
Therefore, the assessment of the sustainability of decolo-
nization measures is one important aspect in the follow-
up measures of our investigation.
A main goal of the HICARE joint research project is
to integrate fragmented compulsory hygiene measures
into a comprehensive hygiene concept. This concept, in
Fig. 4 Data management activities and responsibilities
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addition to expanding upon basic hygiene, encompasses
specific measures for the prevention and treatment of
MRSA, VRE and MRGN. The project will be imple-
mented and evaluated for the model region within the
framework of the HARMONIC study. Since not all facets
can be considered in the evaluation due to personnel and
financial constraints, the screening rate of high risk patients
and frequency of MRSA decolonization treatment upon in-
dication are defined as main study outcomes. Hence, early
recognition of MDROs and professional treatment are the
main objectives of the HICARE project.
While implementing the prevention strategies, specific
conditions of the participating hospitals are considered. In
addition to optimizing processes and providing advanced
training for HCWs, a further goal is to provide patients
with information on how to prevent infections (e.g. correct
disinfection of hands during their stay in the hospital).
Strengths and limitations
An intervention with such a wide approach has strengths,
but it also has limitations. One strength of this project is
that by contributing to the regional management of
MDROs, other regions can profit from the findings on the
implementation of the structure and processes. On the
other hand, possible effects of the study cannot be as-
cribed to individual interventions, but rather are the result
of the total intervention program combined with changes
motivated by external factors, including campaigns initi-
ated by the local government, or regional public health of-
fices. The nested studies are designed to provide insight
into the cost-benefit aspects, the health-related quality of
life, as well as the risk profiles of the various MDROs. The
HARMONIC study has a highly interdisciplinary basis,
providing insight into medical and nursing care, epidemi-
ology and health economics. These may provide a basis
for decisions in health care policies.
A limitation of our study is that it was not possible to
provide direct financial support to the hospitals for the
additional cost incurred by the implementation of the
program. It was therefore necessary to find a workable
model that could be implemented within the framework
of daily hospital routine. Consequently, it was necessary
for certain aspects to fall back on the current documen-
tation of the hospital; e.g. for microbiologic results, it
was necessary to rely on the hospital laboratory rather
than on the installation of a central diagnostics. This
could, however, prove to be a strength in the long run,
as we had to find solutions that are likely to be sustain-
able under routine conditions.
The following factors were taken into consideration in
the conception of the HARMONIC study:
 Limitations of staffing resources (e.g. for
documentation of hygiene measures)
 Limitations of financial resources (e.g. for additional
screening examinations)
 Structural factors of the hospitals (e.g. number of
single rooms, staff / patient ratio)
The HICARE hygiene management system was tailored
to the possibilities and requirements of the individual hos-
pitals by a mutual coordination process. The results
of this coordination are documented in detail and will
be taken into consideration in the evaluation of the
project. This approach was designed to achieve a re-
gional standard for hygiene recommendations based
on scientific evidence that is affordable for the hospi-
tals. Close collaboration with the staff responsible for
hygiene and with the policy makers of the hospitals
should ensure that these hygiene measures will be
sustainably implemented after the end of the study.
Despite the limitations, we believe that with the de-
sign of this study and the chosen parameters, the
groups will be comparable.
An important topic would be the incidence of
MDROs before and after the intervention. Unfortu-
nately, our investigation does not collect sufficient data
to analyze questions referring to MDRO incidence. Due
to limited financial resources, as mentioned above, we
were not able to conduct additional diagnostics to
analyze this outcome.
In 2011, parts of the German infection protection act
were changed and further complemented in 2013. The
law says that the heads of defined medical institutions
have to ensure that measures according to the current
standard of medical science have to be applied to pre-
vent the spread of nosocomial infections, especially
those with multidrug resistance. It is assumed that this
standard is applied when the recommendations of the
“commission for hospital hygiene and infection protec-
tion” are considered. In the HARMONIC study, we
support regional acute hospitals to implement those rec-
ommendations timely and effectively, implementing con-
sistent processes that can be adapted to local challenges,
and managed and monitored. Nevertheless, at least some
of the control hospitals are assumed to have already im-
plemented the national recommendations. However, the
extent may differ due to limited strategic resources, so an
improvement as a result of our intervention is expected.
Implications
The results of the HARMONIC study are expected to
have a direct impact on clinical practice, improving the
effectiveness of targeted screening and multibarrier mea-
surements. Further goals are:
 Improvements and standardization of the MDRO
patient transfer process to the physician responsible
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for further treatment (usually the patient’s general
practitioner)
 Improvement of the practice of antibiotics
prescription
 Improvement of the quality of care (e.g. treatment
of MRSA)
 Informing patients about MDROs
Hospitals are presently facing increasing competition.
Participation in programs such as these allow a facility
to demonstrate that they are actively taking action
against the proliferation of MDROs, thereby providing
protection both to patients and health care workers.
The results of this study will indicate whether or
not it is worth the effort, both economically and from
the standpoint of patient safety and satisfaction, to
continue with this hygiene regimen after the end of
the HARMONIC study.
The website www.hicare.de provides information on
the HARMONIC study and provides links to additional
information on the HICARE joint research project.
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